Key result
The proposed clinical use of beta(2)-adrenoceptor agonists for muscle wasting diseases requires consideration of potential cardiac side effects, including an increased probability of arrhythmias.
Why the study?
What are the cardiac implications of using beta-2 adrenoceptor agonists for the management of muscle wasting?
Population
Patients with muscle wasting diseases
Design
Review
Authors
Loading...
Alerts clinicians to arrhythmia risk with beta-2 agonists in muscle wasting; leaves open need for prospective cardiac safety trials.
What are the cardiac implications of using beta-2 adrenoceptor agonists for the management of muscle wasting?
The use of beta-2 adrenoceptor agonists for muscle wasting may carry a risk of cardiac arrhythmias in susceptible patients.
Molenaar et al. (2006) conducted a review in Muscle wasting diseases. beta(2)-adrenoceptor agonists was evaluated. The proposed clinical use of beta(2)-adrenoceptor agonists for muscle wasting diseases requires consideration of potential cardiac side effects, including an increased probability of arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: